Resultados da busca - Keith W. Pratz

Refinar Resultados
  1. 1
    Acute myeloid leukemia in the elderly: therapeutic options and choice

    Acute myeloid leukemia in the elderly: therapeutic options and choice por Jonathan Webster, Keith W. Pratz

    Publicado em 2017
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  2. 2
    How I treat FLT3-mutated AML

    How I treat FLT3-mutated AML por Keith W. Pratz, Mark J. Levis

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    Recent advances in targeted therapies in acute myeloid leukemia

    Recent advances in targeted therapies in acute myeloid leukemia por Rahul S. Bhansali, Keith W. Pratz, Catherine Lai

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  4. 4
    Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia

    Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia por R. Li, N. Sobreira, P. Dane Witmer, Keith W. Pratz, Evan M. Braunstein

    Publicado em 2016
    Obter o texto integral
    Carta
    Salvar na lista
    Na minha lista:
  5. 5
    FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

    FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML por Keith W. Pratz, Takashi Sato, Kathleen M. Murphy, Adam Stine, Trivikram Rajkhowa, Mark J. Levis

    Publicado em 2009
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  6. 6
    Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia

    Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia por Jessica K. Altman, James M. Foran, Keith W. Pratz, Denise Trone, Jorge E. Cortés, Martin S. Tallman

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients

    Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients por Maria Cristina Villarroel, Keith W. Pratz, Linping Xu, John J. Wright, B. Douglas Smith, Michelle A. Rudek

    Publicado em 2011
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study por Alexander E. Perl, Naval Daver, Keith W. Pratz, Joseph Maly, Wan‐Jen Hong, Erkut Bahceci, Bo Tong, Tian Tian, Kimberley Dilley

    Publicado em 2019
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  9. 9
    Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies

    Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies por J. Kyle Bruner, S. Hayley, Li Li, Alice Can Ran Qin, Michelle A. Rudek, Richard J. Jones, Mark J. Levis, Keith W. Pratz, Christine A. Pratilas, Donald Small

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

    A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response por Keith W. Pratz, Jorge E. Cortés, Gail J. Roboz, Niranjan Rao, Omotayo Arowojolu, Adam Stine, Yukimasa Shiotsu, Aiko Shudo, Shiro Akinaga, Donald Small, Judith E. Karp, Mark J. Levis

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  11. 11
    Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax and Azacitidine

    Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax and Azacitidine por Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Vinod Pullarkat, Brian A. Jonas, Christian Récher, Sunil Babu, Andre C. Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda Chyla, Courtney D. DiNardo

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  12. 12
    HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation

    HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation por Amer M. Zeidan, Patrick M. Forde, Heather J. Symons, Allen Chen, Benjamin D. Smith, Keith W. Pratz, Hetty E. Carraway, Douglas E. Gladstone, Ephraim J. Fuchs, Leo Luznik, Richard J. Jones, Javier Bolaños‐Meade

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  13. 13
    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML por Amy Sexauer, Alexander E. Perl, Xiaochuan Yang, Michael J. Borowitz, Christopher D. Gocke, Trivikram Rajkhowa, Christian Thiede, Mark G. Frattini, Grant E. Nybakken, Keith W. Pratz, Judith E. Karp, B. Douglas Smith, Mark J. Levis

    Publicado em 2012
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  14. 14
    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms por Joshua F. Zeidner, J. E. Karp, Amanda L. Blackford, B. D. Smith, Ivana Gojo, Steven D. Gore, Mark J. Levis, Hetty E. Carraway, Judith M. Greer, S. Percy Ivy, Keith W. Pratz, Michael A. McDevitt

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  15. 15
    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) por Keith W. Pratz, Mohamad Cherry, Jessica K. Altman, Brenda Cooper, José C. Cruz, Joseph G. Jurcic, Mark J. Levis, Tara L. Lin, Alexander E. Perl, Nikolai A. Podoltsev, Gary J. Schiller, Chaofeng Liu, Erkut Bahceci

    Publicado em 2018
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  16. 16
    Impact of <i>F</i> <i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

    Impact of <i>F</i> <i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia por Marina Konopleva, Michael J. Thirman, Keith W. Pratz, Jacqueline S. Garcia, Christian Récher, Vinod Pullarkat, Hagop M. Kantarjian, Courtney D. DiNardo, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Catherine L. Miller, Andrew H. Wei

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  17. 17
    A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

    A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias por Keith W. Pratz, E Cho, Mark J. Levis, Judith E. Karp, Steven D. Gore, Michael A. McDevitt, Adam Stine, Ming Zhao, Sharyn D. Baker, Michael A. Carducci, James R. Wright, Michelle A. Rudek, B. Douglas Smith

    Publicado em 2010
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  18. 18
    Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy

    Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy por Daniel A. Pollyea, Keith W. Pratz, Brian A. Jonas, Anthony Letai, Vinod Pullarkat, Andrew H. Wei, Marina Konopleva, Christian Récher, Olga Frankfurt, David A. Rizzieri, Tu Xu, Monique Dail, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo

    Publicado em 2018
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  19. 19
    ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

    ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine por Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Monique Dail, Grace Ku, Yan Sun, Jalaja Potluri, Brenda Chyla, Daniel A. Pollyea

    Publicado em 2022
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  20. 20
    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study por Daniel A. Pollyea, Keith W. Pratz, Anthony Letai, Brian A. Jonas, Andrew H. Wei, Vinod Pullarkat, Marina Konopleva, Michael J. Thirman, Martha Arellano, Pamela S. Becker, Brenda Chyla, Wan‐Jen Hong, Qi Jiang, Jalaja Potluri, Courtney D. DiNardo

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: